BofA Skipping Celebration of Madrigal's Rezdiffra -- Market Talk

Dow Jones04-22

1121 ET - Madrigal Pharmaceuticals has won many fans on Wall Street since scoring the first FDA approval of a drug to treat the fatty liver disease known as MASH, but Bank of America isn't among them. BofA analyst Alexandria Hammond initiates coverage of Madrigal with an underperform rating and a $150 price objective, saying payer pushback on the $47,000 annual price tag of the drug, Rezdiffra, could prompt a slow launch. BofA says it sees meaningful commercial hurdles that are likely to limit Madrigal's upside potential, and the firms forecast peak sales of $4.1 billion, below Wall Street's $5.5 billion consensus. BofA also warns that Madrigal's lean pipeline gives it limited downside protection. Madrigal down 6.1% to $199.15. (colin.kellaher@wsj.com)

(END) Dow Jones Newswires

April 22, 2024 11:21 ET (15:21 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429329973?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-22 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429329973","market":"fut","top_or_hot":-1,"title":"BofA Skipping Celebration of Madrigal's Rezdiffra -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1121 ET - Madrigal Pharmaceuticals has won many fans on Wall Street since scoring the first FDA approval of a drug to treat the fatty liver disease known as MASH, but Bank of America isn't among them. BofA analyst Alexandria Hammond initiates coverage of Madrigal with an underperform rating and a $150 price objective, saying payer pushback on the $47,000 annual price tag of the drug, Rezdiffra, could prompt a slow launch. BofA says it sees meaningful commercial hurdles that are likely to limit Madrigal's upside potential, and the firms forecast peak sales of $4.1 billion, below Wall Street's $5.5 billion consensus. BofA also warns that Madrigal's lean pipeline gives it limited downside protection. Madrigal down 6.1% to $199.15. (colin.kellaher@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2024 11:21 ET (15:21 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BofA Skipping Celebration of Madrigal's Rezdiffra -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBofA Skipping Celebration of Madrigal's Rezdiffra -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1121 ET - Madrigal Pharmaceuticals has won many fans on Wall Street since scoring the first FDA approval of a drug to treat the fatty liver disease known as MASH, but Bank of America isn't among them....</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2429329973","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429329973","pubTimestamp":1713799260,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1121 ET - Madrigal Pharmaceuticals has won many fans on Wall Street since scoring the first FDA approval of a drug to treat the fatty liver disease known as MASH, but Bank of America isn't among them. BofA analyst Alexandria Hammond initiates coverage of Madrigal with an underperform rating and a $150 price objective, saying payer pushback on the $47,000 annual price tag of the drug, Rezdiffra, could prompt a slow launch. BofA says it sees meaningful commercial hurdles that are likely to limit Madrigal's upside potential, and the firms forecast peak sales of $4.1 billion, below Wall Street's $5.5 billion consensus. BofA also warns that Madrigal's lean pipeline gives it limited downside protection. Madrigal down 6.1% to $199.15. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","MDGL":"Madrigal Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"美国银行跳过牧歌的Rezdiffra庆祝活动——市场谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":0.9},"content_text":"1121 ET - Madrigal Pharmaceuticals has won many fans on Wall Street since scoring the first FDA approval of a drug to treat the fatty liver disease known as MASH, but Bank of America isn't among them. BofA analyst Alexandria Hammond initiates coverage of Madrigal with an underperform rating and a $150 price objective, saying payer pushback on the $47,000 annual price tag of the drug, Rezdiffra, could prompt a slow launch. BofA says it sees meaningful commercial hurdles that are likely to limit Madrigal's upside potential, and the firms forecast peak sales of $4.1 billion, below Wall Street's $5.5 billion consensus. BofA also warns that Madrigal's lean pipeline gives it limited downside protection. Madrigal down 6.1% to $199.15. (colin.kellaher@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2024 11:21 ET (15:21 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429329973"}